Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium

Background: Routine human papillomavirus (HPV) immunization in Belgium is currently regionally managed, with school-aged girls receiving the 9-valent HPV (9vHPV) vaccine in Flanders and Wallonia-Brussels with a national catch-up program for females only. This study will assess whether expanding these programs to gender-neutral vaccination (GNV) with the 9vHPV vaccine is a cost-effective strategy in Belgium.Methods: A validated HPV-type transmission dynamic model estimated the potential health and economic impact of regional vaccination programs, comparing GNV versus female-only vaccination (FO... Mehr ...

Verfasser: Steven Simoens
Andre Bento-Abreu
Barbara Merckx
Sophie Joubert
Steve Vermeersch
Andrew Pavelyev
Stefan Varga
Edith Morais
Dokumenttyp: Artikel
Erscheinungsdatum: 2021
Reihe/Periodikum: Frontiers in Pharmacology, Vol 12 (2021)
Verlag/Hrsg.: Frontiers Media S.A.
Schlagwörter: HPV / human papillomavirus / vaccine / cervical cancer / genital warts / cost-effectiveness / Therapeutics. Pharmacology / RM1-950
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-27391382
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://doi.org/10.3389/fphar.2021.628434